CClinicalTrials.gg
CompletedNCT07062783Updated Aug 5, 2026

Effect of Aerobic Exercise on Biomarkers in Depression

An interventional study of Breathing exercise and Aerobic Exercise in Major Depression, sponsored by Kutahya Health Sciences University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Kutahya Health Sciences University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2024, registered Jul 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study aims to investigate changes in the levels of biomarkers (IGF-1, FGF2, and EGF) involved in neuron development in patients diagnosed with major depression through the effects of breathing exercises and aerobic exercise, as well as to examine the levels of biomarkers (TNF-α, IL-6, and IL-1) and oxidative stress (TAS, TOS, MDA, and F2-isoprostane) that are thought to play a role in the pathophysiology of depression.

02

Conditions studied

  • Major Depression

Keywords

  • Depression
  • Aerobic exercise
  • Oxidative stress
  • Growth factors
03

In context

Depressive Disorder, Major

2,741 studies on the registry are indexed under Depressive Disorder, Major; 559 are open to participants now.

This study's enrollment of 40 is below the median of 80 across 2,283 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Kutahya Health Sciences University is the lead sponsor of 209 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals who volunteer to participate in the study,
  • Between the ages of 18 and 40,
  • Have been diagnosed with clinical depression by a psychiatrist according to DSM-5 criteria

Exclusion criteria

Exclusion Criteria:

  • Individuals with chronic conditions accompanying depression,
  • Those with walking difficulties
  • Those with respiratory system disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Exercise Group

    Those included in the experimental group continued diaphragmatic breathing exercises every day for three weeks and walking exercises at least three days a week.

    Other: Breathing exercise · Other: Aerobic Exercise

  • No intervention
    Control group

    The control group continued their routine lives, and at the end of three weeks

Interventions

  • OtherBreathing exercise

    Volunteers participating in the study who were included in the experimental group performed breathing exercises every day for three weeks. They were taught to focus their attention on the hand on their abdominal area while breathing slowly through their nose and to increase abdominal movement while reducing chest movement. They were warned that during inspiration, as air filled their lungs, the hand on their abdomen should rise upward and the hand on their chest should not move excessively. Participants continued the training until they performed the exercise correctly. The diaphragmatic breathing exercise was performed for 10 minutes in the supine position during the first week, in the semi-sitting and/or sitting position during the second week, and in the standing position during the final week.

  • OtherAerobic Exercise

    The ratios determined as reference values for walking training in healthy adults (reference value for women = (2.11\*height) - (2.29\*body weight) - (5.78\*age) + 667 meters - reference value for men = (7.57\*height) - (1.76\*body weight) - (5.0 2\*age) - 309 meters) was performed at 80% intensity for at least 30 minutes on at least 3 days a week for 3 weeks. Aerobic exercise was considered for 3 weeks to facilitate adaptation to exercise and sustainability.

06

What researchers measure

Primary outcomes

  1. Oxidative stress biomarkers

    It has been reported that the interaction between oxidative stress and the immune system is important, and that activated immune inflammatory pathways can trigger oxidative stress. In our study, an ELISA test will be conducted to investigate how exercise affects the levels of oxidative stress (TAS, TOS, MDA, and F2-isoprostane) biomarkers, which play a role in the pathophysiology of depression.

    Time frame: From enrollment to the end of treatment at 3 weeks

  2. Proinflmatuar sytokines

    It is believed that increased production of key proinflammatory cytokines such as interleukin tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 (IL-1) and acute phase reactants plays an important role in the development of depression as a result of immune system involvement. In our study, an ELISA test will be conducted to investigate how exercise affects the levels of inflammation (TNF-α, IL-6, IL-1) which play a role in the pathophysiology of depression.

    Time frame: From enrollment to the end of treatment at 3 weeks

07

Study locations

1 site
  • Kutahya Health Sciences University
    Kütahya, Merkez 43020, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07062783
Lead sponsor
Kutahya Health Sciences University
Collaborators
Kutahya Health Sciences University Scientific Research Projects Coordination Unit
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Aug 1, 2024
Primary completion
Aug 31, 2025
Completion
Sep 30, 2025
Last update
Aug 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion